Prevalence of non-insulin-dependent diabetes mellitus and related vascular diseases in southwestern arseniasis-endemic and nonendemic areas in Taiwan

Environmental Health Perspectives

Volumn 111, Issue 2, 2003, Pages 155-159

  Wang, Shu Li ^a,b   Chiou, Jeng Min ^a   Chen, Chien Jen ^c   Tseng, Chin Hsiao ^d   Chou, Wei Ling ^a   Wang, Cheng Chung ^e   Wu, Trong Neng ^f   Chang, Louis W ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e Department of Health   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Arsenic; Diabetic complications; Environmental health; Epidemiology; Health insurance; Non insulin dependent diabetes mellitus; Vascular diseases

Indexed keywords

ARSENIC;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENDEMIC DISEASE; FEMALE; GEOGRAPHIC DISTRIBUTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; TAIWAN; VASCULAR DISEASE;

EID: 0037294438     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.5457     Document Type: Article

References (55)

1. Brouwer OF, Onkenhout W, Edelbroek PM, de Kom JF, de Wolff FA, Peters AC. 1992. Increased neurotoxicity of arsenic in methylenetetrahydrofolate reductase deficiency. Clin Neurol Neurosurg 94:307-310.
2. Chait A, Bierman EL. 1994. Pathogenesis of macrovascular diseases in diabetes. In: Joslin's Diabetes Mellitus (Kahn CR, Weir GC, eds). 13th ed. Philadelphia:Lea & Febiger, 648-664.
3. Chang WC, Chen SH, Wu HL, Shi GY, Morota S, Morita I. 1991. Cytoprotective effect of reduced glutathione in arsenical-induced endothelial cell injury. Toxicology 69:101-110.
4. Chen CJ, Chiou HY, Chiang MH, Lin LJ, Tai TY. 1996. Dose-response relationship between ischemic heart disease mortality and long-term arsenic response. Arterioscler Thromb Vasc Biol 16:504-510.
5. Chen CJ, Chiou HY, Huang WI, Chen SY, Hsueh YM, Tseng CH, et al. 1997a. Systemic non-carcinogenic effects and developmental toxicity of inorganic arsenic. In: Arsenic: Exposure and Health Effects (Abernathy CO, Calderon RL, Chappell WR, eds). London:Chapman & Hall, 124-134.
6. Chen CJ, Hsu LI, Tseng CH, Hseuh YM, Chio HY. 1999. Emerging epidemics of arseniasis in Asia. In: Arsenic Exposure and Health Effects (Chappell WR, Abemathy CO, Calderon RL, eds). New York:Elsevier Science, 113-121.
7. Chen CJ, Hsueh YM, Chiou HY, Hsu YH, Chen SY, Horng SF, et al. 1997b. Human carcinogenicity in inorganic arsenic. In: Arsenic: Exposure and Health Effects (Abernathy CO, Calderon RL, Chappell WR, eds). London: Chapman & Hall, 232-242.
8. Chen CJ, Hsueh YM, Lai MS, Shyu MP, Chen SY, Wu MM, et al. 1995. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 25:53-60.
9. Chen CJ, Kuo TL, Wu MM. 1998a. Arsenic and cancers. Lancet 1(8582):414-415.
10. Chen CJ, Wu MM, Lee SS, Wang JD, Chang SH, Wu HY. 1998b. Atherogenicity and carcinogenicity of high-arsenic artesian well water-multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis 8:452-460.
11. Cheng SH, Chiang TL 1997. The effect of universal health insurance on health care utilization in Taiwan. Results from a natural experiment. JAMA 278:89-93.
12. Chiang TL. 1997. Taiwan's 1995 health care reform. Health Policy 39:225-239.
13. Chiou HY, Hsueh YM, Hsieh LL, Hsu LL, Hsu YH, Hsieh FI, et al. 1997a. Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan. Mutat Res 386:197-207.
14. Chiou HY, Huang WI, Su CL, Chang SF, Hsu YH, Chen CJ. 1997b. Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke 28:1717-1723.
15. Curcio F, Ceriello A. 1992. Decreased cultured endothelial cell proliferation in high glucose medium is reversed by antioxidants: new insights on the pathophysiological mechanisms of diabetic vascular complications. In vitro Cell Dev Biol 28A:787-790.
16. del Razo LM, Quintanilla-Vega B, Brambila-Colombres E, Calderon-Aranda ES, Manno M, Albores A. 2001. Stress proteins induced by arsenic. Toxicol Appl Pharmacol 177:132-148.
17. DOH. 1995-1999. National Health Insurance Annual Statistical Report. Taipei, Taiwan:Bureau of National Health Insurance, Department of Health.
18. DOH. 2002. About the Program. Taipei, Taiwan-Bureau of National Health Insurance, Department of Health. Available: http://www.nhi.gov.tw/00english/e_index.htm [accessed 20 June 2002].
19. DOH and BCMH. 1999. First Report on National Health Insurance Health Care Service Analyses for the International Collaborative Project of Business, Technical and Informatics Consulting Services. Taipei, Taiwan:Bureau of National Health Insurance, Department of Health/Victoria, BC:British Columbia Ministry of Health.
20. Fladeby C, Serck-Hanssen G. 1999. Stress-induced glucose uptake in bovine chromaffin cells: a comparison of the effect of arsenite and anisomycin. Biochim Biophys Acta 1452:313-321.
21. Frost SC, Lane MD. 1985. Evidence for the involvement of vicinal sulfhrydryl groups in insulin-activated hexose transport by 3T3-L1 adipocytes. J Biol Chem 260:2646-2652.
22. Gopaul NK, Manraj MD, Hebe A, Lee Kwai Yan S, Johnston A, et al. 2001. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia 44:706-712.
23. Harris AI, Hadden WC, Knowler WC, Bennett PH. 1987. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 years. Diabetes Care 36:523-534.
24. Henriksen EJ, Holloszy JO. 1990. Effects of phenylarsine oxide on stimulation of glucose transport in rat skeletal muscle. Am J Physiol 258(4 pt 1):C648-C653.
25. Hughes MF, Thompson DJ. 1996. Subchronic dispositional and toxicological effects of arsenate administered in drinking water to mice. J Toxicol Environ Health 49:177-196.
26. IARC, 1980. Some Metals and Metallic Compounds. IARC Monogr Eval Carcinog Risks Hum 23:39-141.
27. Jhun BH, Hah JS, Jung CY. 1991. Phenylarsine oxide causes an insulin-dependent, GLUT4-specific degradation in rat adipocytes. J Biol Chem 266:22260-22265.
28. King GL, Banskota NK. 1994. Mechanisms of diabetic microvascular complications. In: Joslin's Diabetes Mellitus (Kahn CR, Weir GC, eds). 13th ed. Philadelphia:Lea & Febiger, 631-647.
29. Krolewski AS, Warram JH. 1994. Onset of the complications of diabetes - epidemiology of late complications of diabetes. In: Joslin's Diabetes Mellitus (Kahn CR, Weir GC, eds). 13th ed. Philadelphia:Lea & Febiger, 605-619.
30. Kuzuya T. 1994. Prevalence of diabetes mellitus in Japan compiled from literature. Diabetes Res Clin Pract 24:S15-S21.
31. Lai MS, Hseuh YM, Chen CJ, Shyu MP, Chen SY, Kuo TL, et al. 1994. Ingested inorganic arsenic and prevalence of diabetes mellitus. Am J Epidemiol 139:484-492.
32. Lewis DR. 1999. Drinking water arsenic: the Millard County, Utah mortality study. In: Arsenic Exposure and Health Effects (Chappell WR, Abernathy CO, Calderon RI, eds). New York:Elsevier, 133-140.
33. Liebl B, Muckter H, Doklea E, Fichtl B, Forth W. 1995. Influence of 2,3-dimercaptopropanol and other sulfur compounds on oxophenylarsine-mediated inhibition of glucose uptake in MDCK cells. Analyst 120:771-774.
34. Longnecker MP, Daniels JL. 2001. Environmental contaminants as etiologic factors for diabetes. Environ Health Perspect 109(suppl 6):871-876.
35. Lorenzi M. 1992. Glucose toxicity in the vascular complications of diabetes: the cellular perspective. Diabetes Metab Rev 8:85-103.
36. Lynn S, Gurr JR, Lai HT, Jan KY. 2000. NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. Circ Res 86:514-519.
37. Mahajan SK, Aggarwal HK, Wig N, Maitra S, Chugh SN. 1992. Arsenic induced neuropathy. J Assoc Physicians India 40:268-269.
38. Mitchell RD, Ayala-Fierro F, Carter DE. 2000. Systemic indicators of inorganic arsenic toxicity in four animal species. J Toxicol Environ Health A 59:119-134.
39. Morales KH, Ryan L, Kuo TL, Wu MM, Chen CJ. 2000. Risk of internal cancers from arsenic in drinking water. Environ Health Perspect 108:655-661.
40. Pan WH, Yeh WT, Hwu CM, Ho NT. 1998. Diabetes prevalence and recognition in Taiwan. In: National Nutrition Survey 1993-1996 in Taiwan (Pan WH, ed). Taipei, Taiwan:Department of Health, Executive Yuan, 279-290.
41. Rahman M, Axelson O. 1995. Diabetes mellitus and arsenic exposure: a second look at case-control data from a Swedish copper smelter. Occup Environ Med 52:773-774.
42. Rahman M, Tondel M, Ahmad SA, Axelson O. 1998. Diabetes mellitus associated with arsenic exposure in Bangladesh. Am J Epidemiol 148:198-203.
43. Rahman M, Wingren G, Axelson O. 1995. Diabetes mellitus among Swedish art glass workers - an effect of arsenic exposure. Scand J Work Environ Health 22:146-149.
44. Singh RB, Bajaj S, Niaz MA, Rastogi SS, Moshiri M. 1998. Prevalence of type 2 diabetes mellitus and risk of hypertension and coronary artery disease in rural and urban population with low rates of obesity. Int J Cardiol 66:65-72.
45. Suzuki KT, Tomita T, Ogra Y, Ohmichi M. 2001. Glutathione-conjugated arsenics in the potential hepato-enteric circulation in rats. Chem Res Toxicol 14:1604-1611.
46. Tsai SM, Wang TN, Ko YC. 1998. Cancer mortality trends in a blackfoot disease endemic community of Taiwan following water source replacement. J Toxicol Environ Health A 55:389-404.
47. Tsai SM, 1999. Mortality for certain diseases in areas with high levels of arsenic in drinking water. Arch Environ Health 54:186-193.
48. Tseng CH, Chong CK, Chen CJ, Tai TY. 1996. Dose-response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in blackfoot disease endemic villagens in Taiwan. Atherosclerosis 120:125-133.
49. Tseng CH, Tai TY, Chong CK, Tseng CP, Lai MS, Lin BJ, et al. 2000. Long-term arsenic exposure and incidence on noninsulin-dependent diabetes mellitus: a cohort study in arsenic-hyperendemic villages in Taiwan. Environ Health Perspect 108:847-851.
50. Wang CH, Jeng JS, Yip PK, Chen CL, Hsu LI, Hsueh YM, et al. 2002. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation 105:1804-1809.
51. Wang SL, Pan WH, Hwu CM, Ho LT, Lo CH, Lin SL, et al. 1997. Incidence of NIDDM and the effects of gender, obesity and hyperinsulinaemia in Taiwan. Diabetologia 40:1431-1438.
52. Welch AH, Helsel DR, Focazio MJ, Watkins SA. 1999. Arsenic in ground water supplies of the United States. In: Arsenic Exposure and Health Effects (Chappell WR, Abernathy CO, Calderon RL, eds). New York:Elsevier, 9-17.
53. WHO, 1981. Arsenic. Environmental Health Criteria 18. Geneva:World Health Organization.
54. Wu MM, Chiou HY, Wang TW, Hsueh YM, Wang IH, Chen CJ, et al. 2001. Association of blood arsenic levels with increased reactive oxidants and decreased antioxidant capacity in a human population of northeastern Taiwan. Environ Health Perspect 109:1011-1017.
55. Wu MM, Kuo TL, Hwang YH, Chen CJ, 1989. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol 130:1123-1132.